Updated information on the management and treatment of Clostridioides difficile (C. difficile) disease now aligned with the recent Infectious Diseases Society of America guidelines.
Expanded discussion of the role of fidaxomicin and bezlotoxumab in the therapy of C. difficile disease.
This email was sent to newsletter@newslettercollector.com using GovDelivery Communications Cloud on behalf of: HIVinfo · 8600 Rockville Pike · Bethesda, MD 20894 · 888-346-3656